Analysts See $-1.00 EPS for WAVE Life Sciences Ltd. (WVE)

February 23, 2018 - By Nellie Frank

 Analysts See $ 1.00 EPS for WAVE Life Sciences Ltd. (WVE)

Analysts expect WAVE Life Sciences Ltd. (NASDAQ:WVE) to report $-1.00 EPS on March, 15.They anticipate $0.21 EPS change or 26.58 % from last quarter’s $-0.79 EPS. After having $-0.94 EPS previously, WAVE Life Sciences Ltd.’s analysts see 6.38 % EPS growth. The stock decreased 0.78% or $0.4 during the last trading session, reaching $50.6. About 112,162 shares traded. WAVE Life Sciences Ltd. (NASDAQ:WVE) has risen 36.01% since February 23, 2017 and is uptrending. It has outperformed by 19.31% the S&P500.

WAVE Life Sciences Ltd. (NASDAQ:WVE) Ratings Coverage

Among 5 analysts covering WAVE Life Sciences (NASDAQ:WVE), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. WAVE Life Sciences had 5 analyst reports since December 7, 2015 according to SRatingsIntel. Suntrust Robinson initiated the stock with “Buy” rating in Monday, December 7 report. The rating was initiated by Leerink Swann on Monday, December 7 with “Outperform”. The firm has “Mkt Outperform” rating by JMP Securities given on Monday, December 7. The stock of WAVE Life Sciences Ltd. (NASDAQ:WVE) earned “Buy” rating by SunTrust on Monday, December 7. The rating was initiated by Jefferies on Monday, December 7 with “Buy”.

WAVE Life Sciences Ltd., a genetic medicines company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company has market cap of $1.41 billion. The firm is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It currently has negative earnings. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system.

More notable recent WAVE Life Sciences Ltd. (NASDAQ:WVE) news were published by: which released: “Here’s Why Wave Life Sciences Fell as Much as 12.1% This Morning” on April 12, 2017, also with their article: “Wave Life Sciences Reports Second Quarter 2017 Financial Results and Provides …” published on August 09, 2017, published: “WAVE Life Sciences Reports First Quarter 2017 Financial Results and Provides …” on May 10, 2017. More interesting news about WAVE Life Sciences Ltd. (NASDAQ:WVE) were released by: and their article: “Wave Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 …” published on July 17, 2017 as well as‘s news article titled: “Wave Life Sciences: DMD Program Set To Create Value In 2018” with publication date: November 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.